Q2040 — Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
Q2040 is a HCPCS Level II code for tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion. It belongs to the Temporary Codes section. It was terminated on December 31, 2018 and is not valid on new claims.
This code has been terminated
CMS terminated Q2040 on December 31, 2018. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q2040
- Long descriptor
- Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
- Short descriptor
- Tisagenlecleucel car-pos t
- Added
- January 1, 2018
- Terminated
- December 31, 2018
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to Q2040
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q2040 is not quite right, the correct code is very often within a few positions of it.
- Q2026Injection, radiesse, 0.1 ml
- Q2028Injection, sculptra, 0.5 mg
- Q2034Influenza virus vaccine, split virus, for intramuscular use (agriflu)
- Q2035Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
- Q2036Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
- Q2037Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
- Q2038Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
- Q2039Influenza virus vaccine, not otherwise specified
- Q2041Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2042Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2043Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
- Q2049Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
- Q2050Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
- Q2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)
- Q2053Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2054Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Questions about Q2040
What is HCPCS code Q2040?
Q2040 is a HCPCS Level II code for tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion. It sits in the Temporary Codes section.
Does Medicare cover Q2040?
The CMS HCPCS file marks Q2040 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is Q2040 still valid?
No. Q2040 was terminated on December 31, 2018 and should not be used on new claims.